Home > Boards > US OTC > Medical - Healthcare > Wize Pharma Inc. (WIZP)

Can-Fite to Present at the 9th International Congress

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
midastouch017 Member Profile
 
Followed By 110
Posts 24,091
Boards Moderated 14
Alias Born 02/07/04
160x600 placeholder
Quarterly Report (10-q) Edgar (US Regulatory) - 5/15/2020 4:05:28 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/7/2020 9:20:44 AM
Annual Report (10-k) Edgar (US Regulatory) - 3/30/2020 5:33:19 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/9/2020 4:01:03 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 3/5/2020 5:07:49 PM
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 3/4/2020 4:03:49 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/20/2020 4:23:38 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 2:19:05 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 2:17:07 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 2:15:45 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/7/2020 4:32:08 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/6/2020 8:59:48 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/15/2020 4:28:09 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/26/2019 4:32:10 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 12/26/2019 4:31:43 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/20/2019 9:13:37 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/17/2019 4:59:27 PM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 12/13/2019 3:01:38 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/9/2019 5:23:55 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/5/2019 5:14:59 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/14/2019 4:55:36 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 5:25:58 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 5:24:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 5:23:28 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 5:15:40 PM
midastouch017   Tuesday, 03/25/14 07:25:30 AM
Re: None
Post # of 87 
Can-Fite to Present at the 9th International Congress of Autoimmunity

Tuesday 25 March 2014

PETACH TIKVA, Israel, March 25, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has been invited to present at the upcoming 9th International Congress of Autoimmunity. The conference will be held on March 26-30, 2014 at Nice Acropolis Convention Center in Nice, France.

On Friday March 28th, 16:30, Can-Fite CEO Dr. Pnina Fishman will Co-Chair the session of Psoriatic Arthritis, Rheumatoid Arthritis and Ankylosing Spondylitis and deliver a presentation on: 'The A3 adenosine receptor as a therapeutic target and predictive marker in Rheumatoid Arthritis.' In the frame of the presentation Dr. Fishman will present positive data from the recently concluded Phase II Rheumatoid Arthritis and the interim analysis of the Phase II/III Psoriasis studies.

CF101 recently announced a successfully completed Phase II trial data and is set for Phase III of clinical trial testing in the U.S., Europe and Israel. Rheumatoid arthritis is an autoimmune disease and according to WebMD affects about 1% of the American population and millions more around the world. Rheumatoid arthritis is two to three times more common in women than men. According to independent business information provider Visiongain, the global rheumatoid arthritis (RA) drug market is predicted to generate revenues of $38.5 billion in 2017.

"We are excited to be a part of the conference and share our scientific findings and talk about our initiatives for the coming months and our plans for the Phase III Rheumatoid Arthritis study," says Can-Fite CEO Dr. Pnina Fishman. "Combating autoimmune diseases such as rheumatoid arthritis and developing treatments with CF101 have been our goal that is coming to fruition. The conference is a great venue to share research findings, collaborate, share best practices with our peers and learn from one another with a goal of fighting autoimmune diseases."

To arrange a one-on-one meeting with management, please contact Robert Haag at canf@irthcommunications.com or 1-866-976-4784.

About 9th International Congress On Autoimmunity
The 9th International Congress on Autoimmunity is the world's foremost gathering of top experts in immunology, rheumatology, and related fields. First established by renowned autoimmunity expert Professor Yehuda Shoenfeld, the congress will address the genetic, etiology, diagnostic, clinical aspects and novel therapies of 80 autoimmune diseases. Join your colleagues in breathtaking Nice, France, on March 26-30, 2014 and learn about the newest therapeutic techniques and diagnostic tools. Previous meetings were comprised of 81 symposia featuring 600 leading speakers.


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist